enzastaurin
Showing 1 - 25 of 34
Vascular Ehlers-Danlos Syndrome Trial in Englewood (Enzastaurin, Placebo)
Not yet recruiting
- Vascular Ehlers-Danlos Syndrome
- Enzastaurin
- Placebo
-
Englewood, ColoradoAytu BioPharma
Jul 27, 2022
Ovarian Cancer, Tumors, Carcinoma Trial in Philadelphia (enzastaurin)
Completed
- Ovarian Cancer
- +2 more
- enzastaurin
-
Philadelphia, PennsylvaniaGynecologic Oncology Group 215-854-0770
Nov 24, 2020
Lung Cancer Trial in Tampa (Enzastaurin, Placebo)
Completed
- Lung Cancer
- Enzastaurin
- Placebo
-
Tampa, FloridaFor additional information regarding investigative sites for thi
Aug 31, 2020
NSCLC Trial in United States (enzastaurin, pemetrexed, docetaxel)
Completed
- Non-Small Cell Lung Cancer
- enzastaurin
- +3 more
-
Burlington, North Carolina
- +3 more
Apr 20, 2021
Pancreatic Tumor Trial in Dallas (enzastaurin, gemcitabine)
Completed
- Pancreatic Neoplasm
- enzastaurin
- gemcitabine
-
Dallas, TexasFor additional information regarding investigative sites for thi
Aug 17, 2020
Solid Tumor, Lymphoma, Malignant Trial in Beijing, Changsha, Guang Zhou (Enzastaurin)
Completed
- Solid Tumor
- Lymphoma, Malignant
- Enzastaurin
-
Beijing, China
- +2 more
Sep 14, 2020
Tumors, Cancer Trial in Sun City (enzastaurin)
Completed
- Neoplasms
- Cancer
- enzastaurin
-
Sun City, ArizonaFor additional information regarding investigative sites for thi
Jun 9, 2020
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma Trial in San Francisco (enzastaurin, temozolomide, radiation therapy)
Completed
- Glioblastoma
- +2 more
- enzastaurin
- +2 more
-
San Francisco, CaliforniaFor additional information regarding investigative sites for thi
Jul 23, 2020
NSCLC, Malignant Solid Tumor Trial in United States (enzastaurin, erlotinib)
Completed
- Non-Small Cell Lung Cancer
- Malignant Solid Tumor
- enzastaurin
- erlotinib
-
Los Angeles, California
- +9 more
Apr 20, 2021
NSCLC Trial in United States (enzastaurin, pemetrexed, carboplatin)
Completed
- Non-small Cell Lung Cancer
- enzastaurin
- +4 more
-
Bentonville, Arkansas
- +11 more
Apr 20, 2021
Non Small Cell Lung Cancer, Small Cell Lung Cancer Trial in Worldwide (enzastaurin, )
Completed
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- enzastaurin
- placebo
-
Kobenhavn, Denmark
- +6 more
Oct 9, 2020
Waldenstrom's Macroglobulinemia, Multiple Myeloma Trial in France, United States (Enzastaurin)
Completed
- Waldenstrom's Macroglobulinemia
- Multiple Myeloma
- Enzastaurin
-
Boston, Massachusetts
- +3 more
Sep 1, 2020
Solid Tumor, Lymphoma, Malignant Trial in France (warfarin, enzastaurin)
Ovarian Cancer, Fallopian Tube Tumors, Peritoneal Tumor Trial in Worldwide (enzastaurin, carboplatin, paclitaxel)
Completed
- Ovarian Cancer
- +2 more
- enzastaurin
- +3 more
-
Leuven, Belgium
- +14 more
Sep 23, 2020
Prostate Cancer Trial in Germany, Italy, United States (enzastaurin, , docetaxel)
Completed
- Prostate Cancer
- enzastaurin
- +3 more
-
Fullerton, California
- +27 more
Oct 9, 2020
Mantle-Cell Lymphoma Trial in Worldwide (enzastaurin)
Completed
- Mantle-Cell Lymphoma
- enzastaurin
-
Woolloongabba, Queensland, Australia
- +16 more
Jun 9, 2020
Breast Cancer Trial in Worldwide (enzastaurin, , capecitabine)
Terminated
- Breast Cancer
- enzastaurin
- +2 more
-
Buenos Aires, Argentina
- +19 more
Jul 20, 2020
Cutaneous T-Cell Lymphoma Trial in United States (Enzastaurin)
Completed
- Cutaneous T-Cell Lymphoma
- Enzastaurin
-
Birmingham, Alabama
- +15 more
Sep 23, 2020
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor Trial in United States (enzastaurin, irinotecan, cetuximab)
Completed
- Colorectal Cancer
- +2 more
- enzastaurin
- +2 more
-
Casa Grande, Arizona
- +19 more
Jul 20, 2020
Lymphoma, Large Cell, Diffuse Trial in France, Germany, Russian Federation (enzastaurin, gemcitabine, rituximab)
Completed
- Lymphoma, Large Cell, Diffuse
- enzastaurin
- +3 more
-
Creteil, France
- +17 more
Jul 23, 2020
Metastatic Renal Cell Carcinoma Trial in Worldwide (Enzastaurin, Sunitinib, Placebo)
Completed
- Metastatic Renal Cell Carcinoma
- Enzastaurin
- +2 more
-
Vienna, Austria
- +3 more
Sep 3, 2019